Santhosh Kambaiah Nagaraj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Santhosh Kambaiah Nagaraj has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Abinaya Kaliappan
Immunology Section, ICAR - Indian Veterinary Research Institute, Bareilly, India
2 shared publications - Rohan Narayan
Emerging Viral Pathogens Laboratory Infosys Wing Centre for Infectious Disease Research Indian Institute of Science Bengaluru India
2 shared publications - Shashank Tripathi
Emerging Viral Pathogens Laboratory, Centre for Infectious Disease Research, Indian Institute of Science, Bengaluru, India
2 shared publications - Akhila Balakrishna Rai
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, India
1 shared publication - Ankur Singh
Molecular Virology Lab Department of Bioscience and Bioengineering Indian Institute of Technology Roorkee Roorkee Uttarakhand India
1 shared publication Chakenahalli Naveenkumar
Foundation For Neglected Disease Research KIADB Industrial Area Bengaluru India
1 shared publication
Latest Publications
- Open Access
- 22 October 2026
- Published by Wiley in Advanced Science
- p. e78336
An Oral Antiviral Combination Against Severe COVID‐19 Enabled by the Synergistic Mechanisms of Action of Auranofin and Remdesivir
Auranofin, an FDA‐approved oral anti‐rheumatic drug, was previously shown by our group to restrict Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) replication and pathology in preclinical models. Here, we systematically characterized its mechanism of action (MOA) through biochemical drug‐protein interactions, cell‐based mechanistic assays, and preclinical efficacy studies. Auranofin directly binds and inhibits SARS‐CoV‐2 MPro while simultaneously targeting multiple stages of the viral life cycle, disrupting endosomal trafficking, suppressing Spike S1/S2 proteolytic processing, impairing syncytia formation, and attenuating NF‐κB‐driven proinflammatory signaling. In cell culture, Auranofin demonstrated robust synergy with Remdesivir but competed with the MPro inhibitor Nirmatrelvir, informing rational combination design. In mice infected with the SARS‐CoV‐2 Delta variant, the oral combination of Auranofin and the Remdesivir prodrug GS‐621763 outperformed monotherapy, markedly reducing viral replication, inflammatory cytokine responses, and lung pathology, and improving clinical outcomes. These findings establish a multi‐target antiviral MOA of Auranofin and provide a mechanistic rationale for an all‐oral antiviral combination regimen against COVID‐19.
- 22 October 2026
- Published by Wiley in Advanced Science
- p. e78336
Open AccessAn Oral Antiviral Combination Against Severe COVID‐19 Enabled by the Synergistic Mechanisms of Action of Auranofin and Remdesivir
Auranofin, an FDA‐approved oral anti‐rheumatic drug, was previously shown by our group to restrict Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) replication and pathology in preclinical models. Here, we systematically characterized its mechanism of action (MOA) through biochemical drug‐protein interactions, cell‐based mechanistic assays, and preclinical efficacy studies. Auranofin directly binds and inhibits SARS‐CoV‐2 MPro while simultaneously targeting multiple stages of the viral life cycle, disrupting endosomal trafficking, suppressing Spike S1/S2 proteolytic processing, impairing syncytia formation, and attenuating NF‐κB‐driven proinflammatory signaling. In cell culture, Auranofin demonstrated robust synergy with Remdesivir but competed with the MPro inhibitor Nirmatrelvir, informing rational combination design. In mice infected with the SARS‐CoV‐2 Delta variant, the oral combination of Auranofin and the Remdesivir prodrug GS‐621763 outperformed monotherapy, markedly reducing viral replication, inflammatory cytokine responses, and lung pathology, and improving clinical outcomes. These findings establish a multi‐target antiviral MOA of Auranofin and provide a mechanistic rationale for an all‐oral antiviral combination regimen against COVID‐19.
- Open Access
Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. Graphical
Open AccessBroad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. Graphical